Farnesylacetic acid

Recent clinical trials have revealed that two terpenoid derivatives of quite different chemical constitutions may hold some promise as useful chemotherapeutic agents in the treatment of gastric ulcers, although accurate assessment of their therapeutic potentialities must await the fullness of time. These compounds are the disodium salt of the hemisuccinate ester (LXVIII) of 18 -glycyr-rhetinic acid (approved name Carbenoxolone sodium) [505 a] and the geranyl ester (LXIX) of farnesylacetic acid (approved name Gefarnate). 

The first steps of the [ C]squalene synthesis resemble the pathway selected for the synthesis on [3 - C]coenzyme QIO 13061 (Figure 6.84). In this case alkylation with solanesyl bromide (3011 and subsequent hydrolysis and decarboxylation of the ester function converted ethyl [3- C]acetoacetate into [2- C]solanesylacetone 302. Chain extension of 302 in a Homer-Wadsworth-Emmons reaction, reduction of the resulting a,/3-unsatu-rated ester 303 and coupling of the resulting alcohol ([3- C]decaprenol, 3041 to 2-methyl-5,6-dimethoxy-1,4-hydroquinone (3051 provided the coenzyme in an overall radiochemical yield of 8% after oxidation. Methodologically comparable pathways have also been published for the synthesis of [5- C]farnesylacetic acid and [3 - C]menaquinone . 

GEA 6414 tolfenamic acid, gefarnate (ban, inn] (geranyl farnesylacetate) is a tetradecatrienoate, which has been used as a gastric SECRETION INHIBITOR and ANTIIJLCEROGENIC for the treatment of peptic ulcers and other gastrointestinal disorders. GelTears carbomer. 

---